<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03367546</url>
  </required_header>
  <id_info>
    <org_study_id>2017LS101</org_study_id>
    <secondary_id>MT2017-30</secondary_id>
    <nct_id>NCT03367546</nct_id>
  </id_info>
  <brief_title>Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases</brief_title>
  <official_title>Haploidentical Donor T-cell Replete Allogeneic Hematopoietic Cell Transplant Following Reducing Intensity Conditioning for Patients With Selected High Risk Non-Malignant Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II study for the use of T-cell replete reduced intensity conditioning (RIC)
      haploidentical donor allogeneic hematopoietic cell transplantation (HaploHCT) for individuals
      with high-risk non-malignant diseases who lack a suitable HLA-matched sibling donor.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2019</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutrophil Recovery</measure>
    <time_frame>Day 42</time_frame>
    <description>Incidence of neutrophil recovery by day +42</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of overall survival at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Graft Failure (neutropenic and non-neutropenic)</measure>
    <time_frame>Day 42</time_frame>
    <description>Incidence of primary graft failure (neutropenic and non-neutropenic) by day +42</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Thalassemia</condition>
  <condition>High Risk Hematologic Disorders</condition>
  <condition>Cerebral Adrenoleukodystrophy</condition>
  <condition>Inherited Metabolic Disorders</condition>
  <arm_group>
    <arm_group_label>rATG, FLU/CY/TBI, &amp; Thiotepa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-Thymocyte Globulin - Rabbit (rATG), Fludarabine (Fludara), Cyclophosphamide (Cytoxan, Neosar), Total Body Irradiation (TBI), &amp; Thiotepa</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood and Marrow Transplant</intervention_name>
    <description>Reduced intensity conditioning (RIC) with rabbit ATG, fludarabine, cyclophosphamide, thiotepa and low dose (2 Gy) total body irradiation followed by T-cell replete, unmanipulated, haploidentical related donor stem cell transplant (HaploHCT) and post-transplant cyclophosphamide (PTCy)</description>
    <arm_group_label>rATG, FLU/CY/TBI, &amp; Thiotepa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sickle Cell Disease (SCD)

             * If diagnosis of SCD must meet one or more of the following disease characteristics:

               -  Stroke, CNS hemorrhage or a neurologic event lasting longer than 24 hours, or
                  abnormal cerebral MRI or cerebral arteriogram or MRI angiographic study and
                  impaired neuropsychological testing

               -  Acute chest syndrome with a history of recurrent hospitalizations or exchange
                  transfusions

               -  Recurrent vaso-occlusive pain 3 or more episodes per year for 3 years or more
                  years or recurrent priapism,

               -  Impaired neuropsychological function and abnormal cerebral MRI scan

               -  Stage I or II sickle lung disease,

               -  Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration
                  rate [GFR] 30-50% of the predicted normal value)

               -  Bilateral proliferative retinopathy and major visual impairment in at least one
                  eye

               -  Osteonecrosis of multiple joints with documented destructive changes

               -  Requirement for chronic transfusions

               -  RBC alloimmunization

          -  Transfusion Dependent Alpha- or Beta-Thalassemia

          -  Other Non-Malignant Hematologic Disorders:

        Transfusion dependent or involve other potential life-threatening cytopenias, including but
        not limited to Paroxysmal Nocturnal Hemoglobinuria, Glanzmann's Thrombasthenia, Severe
        Congenital Neutropenia and Shwachman-Diamond Syndrome

          -  cALD

               -  Diagnosis of ALD by abnormal plasma very long chain fatty acid (VLCFA) profile or
                  ABCD1 gene mutation

               -  Cerebral disease on MRI

               -  Absence of a Major Functional Disability (cortical blindness, loss of
                  communication, wheelchair dependence) on the ALD Neurologic Function Scale

               -  Performance IQ of 70 or higher

          -  Other inherited metabolic disorders:

        Any other inherited metabolic disorder for which alloHCT is indicated and for whom, in the
        opinion of the treating physician, the patient's best treatment option is with a
        haploidentical donor following non-myeloablatve conditioning.

          -  Age, Performance Status, Consent

               -  Age: 0-25 years

               -  Performance Status: Karnofsky ≥ 70%, Lansky play score ≥ 70

               -  Consent: voluntary written consent (adult or parental/guardian)

          -  Adequate Organ Function

               -  Renal: Creatinine &lt;2.0 mg/dl for adults or glomerular filtration rate &gt; 50 ml/min
                  for children

               -  Hepatic: Bilirubin and ALT &lt;3 times the upper limit of institutional normal

               -  Cardiac: Absence of decompensated congestive heart failure, or uncontrolled
                  arrhythmia and left ventricular ejection fraction &gt; 40%.

        Exclusion Criteria:

          -  Availability of a suitable HLA-matched related donor

          -  Uncontrolled infection

          -  Pregnant or breastfeeding

          -  HIV positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christen L Ebens, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Pediatrics Blood and Marrow Transplant</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kim Nelson, RN</last_name>
    <phone>612-273-2925</phone>
    <email>knelso62@fairview.org</email>
  </overall_contact>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2017</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCD</keyword>
  <keyword>cALD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Adrenoleukodystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

